Company intelligence / Profile preview

Luna Diabetes

San Diego, California, United Stateslunadiabetes.com ↗

Ownership: Private
Development stage: Commercial

Overview

Luna Diabetes has initiated a pivotal clinical trial of its automated insulin delivery system—the world’s smallest patch pump—targeting people with diabetes who use multiple daily injections via insulin pens. The device works overnight to deliver micro-boluses of rapid acting insulin based on continuous glucose monitor data. The primary endpoint of the study is time in range for blood glucose levels. Results are expected in early 2025; commercial launch will follow if successful

Therapeutic areas: Endocrinology
Modalities: Device
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Luna Diabetes.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Luna Diabetes.

Explore the full profile